A Phase 3 interventional study of Bimekizumab in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Active, not recruiting at 16 sites in 3 countries. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 71st largest by enrollment of the 139 interventional ones that give a count, is one of 25 that started in 2025, is one of 24 in phase 3, reaches primary completion later than 14 of the 54 other live ones, and was the 131st registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 9 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is close to the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 6 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants will receive a bimekizumab dose which is weight-dependent.
Drug: Bimekizumab
Bimekizumab will be administered at pre-specified timepoints.
Geometric Mean Plasma bimekizumab concentrations at Week 16
Plasma samples will be collected prior to dosing for measurement of plasma concentrations of bimekizumab at the specified timepoint.
Time frame: At Week 16
Exposure-adjusted incidence rate of Treatment- Emergent Adverse Events (TEAEs) during the Initial Treatment Period
The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to IMP.
Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of Serious TEAEs during the Initial Treatment Period
The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. A SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical events
Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of TEAEs leading to withdrawal during the Initial Treatment Period
The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to IMP.
Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of Selected Safety Topics of Interest (including incidence of infections [serious, opportunistic, fungal, and TB], IBD, and injection site reactions) over the Initial Treatment Period
Safety topics of interest for this study include events for which special monitoring will be for infections (serious, opportunistic, fungal, and tuberculosis \[TB\]), inflammatory bowel disease (IBD), and injection site reactions.
Time frame: Up to Week 16
Mean Change from Baseline in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) at Week 16
Blood pressure (Systolic Blood Pressure and Diastolic Blood Pressure) will be measured in millimeters of mercury (mmHg).
Time frame: Baseline and Week 16
Mean Change from Baseline in vital sign (Pulse rate) at Week 16
Pulse Rate will be measured in beats per minute (beats/min).
Time frame: Baseline and Week 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (glucose, potassium, sodium, calcium) at Weeks 4,12, and 16
Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L).
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine) at Weeks 4,12, and 16
Biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen \[BUN\], and creatinine) will be measured in micromols per liter (μmol/L).
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase) at Weeks 4,12, and 16
Biochemistry parameters (alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) will be measured in units per liter (U/L).
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (hemoglobin) at Weeks 4,12, and 16
Hemoglobin will be measured in grams per liter (g/L).
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (hematocrit) at Weeks 4,12, and 16
Hematocrit will be measured in volume percentage (%) of red blood cells in blood.
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes) at Weeks 4, 12, and 16
Platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes will be measured in number of blood cells per liter (10\^9/L)
Time frame: Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (erythrocytes)
Erythrocytes will be measured in number of red blood cells per liter (10\^12/L).
Time frame: Baseline, Week 4, 12, and 16
Incidence rate for Positive, Negative, Missing Plasma Anti-Bimekizumab Antibodies at Baseline and Week 16
Positive, negative, and missing plasma anti-bimekizumab antibodies detection prior to and following IMP administration during the Initial Treatment Period.
Time frame: Baseline and Week 16
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab